Doxycycline monohydrate

Name: Doxycycline monohydrate
Brand: MedChemExpress
SKU: HY-W008923
Rating: 5.0 (173 reviews)

Cat. No.: HY-W008923 Purity: 98.95%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Doxycycline monohydrate is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline monohydrate is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline monohydrate also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline monohydrate induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline monohydrate also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline monohydrate has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.

For research use only. We do not sell to patients.

CAS No. : 17086-28-1

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 173 publication(s) in Google Scholar

Other Forms of Doxycycline monohydrate:

Doxycycline-d₃ (hyclate) (major) In-stock
Doxycycline In-stock
Doxycycline hydrochloride In-stock
Doxycycline hyclate In-stock
Doxycycline calcium Get quote
Doxycycline monohydrate (Standard) Get quote

173 Publications Citing Use of MCE Doxycycline monohydrate

In Vivo Efficacy Study

IHC

In Vivo Imaging

Cell Imaging/Staining

RT-PCR

ELISA

Microbiological Assay

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 May;45(5):608-631. [Abstract]; Bioluminescence imaging of the lung metastasis burden after inoculation of MKN45 cells with DOX (500 mg/kg, daily, 30 days)-induced CagA expression and MA treatment.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 May;45(5):608-631. [Abstract]; After inoculating MKN45 cells with DOX-induced CagA expression and MA treatment, HE staining was performed on lung tissue sections of a specified group. The quantitative results of the number of lung metastases are shown on the right.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2025 Apr;27(4):641-653. [Abstract]; HeLa cells stably expressing tet-on-shScramble (Scr) or tet-on-shMAT2A were pretreated with Doxycycline hydrochloride (Dox, 1 μg/ mL) for two days, and the cell lysates were analysed by immunoblotting with the indicated antibodies.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 Oct 8;524:169421.; Therapeutic effect of VRC, Doxycycline hydrochloride (Doxy, 0.05 %, 5 μl, 4 times per day for 5 days) on DXMS- associated severe FK. Dynamic phenotype of corneas with different groups observed by slit lamp on each day after infection (n = 6/group).

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Mar 19;44(1):99. [Abstract]; Nude mice (nu/nu) were surgically engrafted intracranially with GSCs labeled with luciferase and transduced with a Doxycycline hydrochloride (DOX)-inducible system for shPHGDH expression. Mice harboring either GSC19 (A) or GSC29 (B) were randomly assigned to treatment groups (6 mice per group). Starting from day 7 or day 9 post-engraftment, as per the study design (A, B, left), treatments were administered: control, 3 Gy ionizing radiation (IR) delivered weekly over three sessions, 2 mg/mL DOX in the drinking water or a combination of IR and DOX. The progression of GBM xenografts was monitored through bioluminescence imaging, and representative images are displayed (A, B, right).

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Nov 25;44(11):116496. [Abstract]; MOLM-13 cells were treated with Doxycycline hydrochloride (25 µM) or Chloramphenicol (25 µM) for 24 h. Mitochondrial translation and MMP were examined (n=3)

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141. [Abstract]; Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. TET, Tetracycline. DOX, Doxycycline. E, Erythromycin. AZI, Azithromycin. P, Penicillin. CAZ, Ceftazidime. AMP, Ampicillin. CEZ, Cefazolin. CEF, Cefotaxime. OXA, Oxacillin. CRO, Ceftriaxone. AMK, Amikacin. GEN, Gentamycin, KANA, Kanamycin. TOB, Tobramycin. SPC, Spectinomycin.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Feb;56(2):294-305. [Abstract]; RT-qPCR analysis of STAT5A and target gene expression in STB-BL with DOX (5 μM, 6 days)-inducible overexpression of STAT5A.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Feb;56(2):294-305. [Abstract]; RT-qPCR analysis of MITF and target gene expression in STB-BL with DOX (5 μM, 6 days)-inducible overexpression of MITF.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Feb;56(2):294-305. [Abstract]; ELISA analysis of CSH2 expression in trophoblast organoids derived from hTSCs-BL with DOX (5 μM, 6 days)-inducible overexpression of MITF.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Feb;56(2):294-305. [Abstract]; Bright fields and immunofluorescence analysis of trophoblast markers (CDH1 and hCG) in trophoblast organoids derived from hTSCs-BL with DOX (5 μM, 6 days)-inducible overexpression of MITF.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Feb;44(2):251-272. [Abstract]; The expression of NHE7 in Dox-inducible NHE7-mAID-KO MHCC97L cells with or without doxycycline (DOX, 2 mg/mL) and indole-3-acetic acid (IAA, 50 μg/mL) treatment for 24 h was examined by immunoblotting.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Feb;44(2):251-272. [Abstract]; Mice orthotopically injected with NHE7-mAID-KO MHCC97L cells were administered vehicle (DMSO), DOX (2 mg/mL in drinking water containing 5% sucrose), IAA (25 mg/kg/day) and sorafenib (30 mg/kg/day) for 2 weeks (n = 6). Bioluminescence imaging of whole mice was performed at the end of the experiment, and the signal intensity was quantified.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Feb;44(2):251-272. [Abstract]; Mice orthotopically injected with NHE7-mAID-KO MHCC97L cells were administered vehicle (DMSO), DOX (2 mg/mL in drinking water containing 5% sucrose), IAA (25 mg/kg/day) and sorafenib (30 mg/kg/day) for 2 weeks (n = 6). Immunohistochemistry of NHE7 and Rab21 in liver tumor tissues.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2020 Sep 9;19(1):139. [Abstract]; ATL cells MT1 stably transfected with a TET-inducible FBXW7 wild type or W425R were induced with doxycycline (2 μg/ml, 24 h) and degradation (WT) or lack thereof (W425R) of endogenous BRAF was confirmed by Western blot.

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2020 Sep 9;19(1):139. [Abstract]; ATL cells MT1 stably transfected with a TET-inducible FBXW7 wild type, endogenous degradation of BRAF by wild type FBXW7 was confirmed by immunohistochemistry following induction of FBXW7 with doxycycline (2 μg/ml, 24 h).

: Doxycycline monohydrate purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2016 Jun 28;376(1):188-96. [Abstract]; Doxycycline inducible shRNA can effectivly knockdown the expression of AKT in HCC cells. Cells are treated with 100ng/mL Doxcycline and cultured for the indicated times.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All MMP Isoform Specific Products:

View All Isoforms

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Tetracycline

Cellular Effect

Cell Line	Type	Value	Description	References
HT-1080	IC₅₀	21.4 μM Compound: 7	Inhibition of cell invasion in human HT-1080 cells for 24 hrs by Calcein AM staining based fluorometric analysis Inhibition of cell invasion in human HT-1080 cells for 24 hrs by Calcein AM staining based fluorometric analysis	[PMID: 35969157]
HeLa	IC₅₀	30 μM Compound: Doxycycline	Compound was evaluated for the inhibition of cell proliferation of human cervix epithelioid carcinoma, HeLa (ATCC CCL2). Compound was evaluated for the inhibition of cell proliferation of human cervix epithelioid carcinoma, HeLa (ATCC CCL2).	10.1016/0960-894X(96)00418-0
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21741131]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21852132]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22889559]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 24946216]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 25282267]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25791675]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 27155463]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27654395]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34364164]
HepG2	IC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19482476]
HepG2	IC₅₀	20 μM Compound: doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19926173]
HepG2	IC₅₀	53 μM Compound: Doxycycline	Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065). Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065).	10.1016/0960-894X(96)00418-0
K562	IC₅₀	15 μM Compound: Doxycycline	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19482476]
K562	IC₅₀	15 μM Compound: doxycycline	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19926173]
THP-1	IC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry	[PMID: 19748781]
THP-1	IC₅₀	3.1 μM Compound: Doxycycline	Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Plasmodium falciparum Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Plasmodium falciparum	[PMID: 19748781]
Vero	IC₅₀	50 μM Compound: Doxycycline	Antiviral activity against DENV2 infected in African green monkey Vero cells assessed as reduction in virus titer after 72 hrs by naphthol blue-black dye based assay Antiviral activity against DENV2 infected in African green monkey Vero cells assessed as reduction in virus titer after 72 hrs by naphthol blue-black dye based assay	[PMID: 31128447]

In Vitro

Doxycycline (11.39 μM + MCF-7; 7.13 μM + MDA-MB-468; 72 h) monohydrate significantly reduces the population of CD44⁺/CD24^-/low breast cancer stem cells in MCF-7 and MDA-MB-468 cells^[2].
Doxycycline (11.39 μM+MCF-7; 7.13 μM+MDA-MB-468; 72 h) monohydrate significantly downregulates the mRNA and protein expression of stem cell markers (Nanog, Oct4, Sox2, c-Myc, CD44) in MCF-7 and MDA-MB-468 breast cancer cells^[2].
Doxycycline (1 μg/mL; 5 d) monohydrate increases the colony formation efficiency of undifferentiated human embryonic stem cells (H9, HSF6, H1, H7, HUES6) and human induced pluripotent stem cells (retrovirus-derived, lentivirus-derived, protein-induced lines), and elevates the number of colonies expressing undifferentiated markers under various culture conditions^[3].
Doxycycline (1 μg/mL; 5 d) monohydrate promotes the survival and proliferation of H9 human embryonic stem cells (hESC) more effectively than Y-27632 (HY-10071), resulting in larger cell colonies, a higher proportion of undifferentiated AP⁺ cells, as well as downregulated expression of pro-apoptotic genes and upregulated expression of pluripotency-related genes^[3].
Doxycycline (1 μg/mL; 6 d; passage 12) monohydrate reduces cell apoptosis, increases S-phase cell accumulation, supports the long-term expansion of H9 human embryonic stem cells (H9 hESCs) and Lenti-1 induced pluripotent stem cells (Lenti-1 hiPSCs) cultured in clusters on MEF feeder layers, and maintains the pluripotency and normal karyotype of the cells during repeated passaging^[3].
Doxycycline (1 μg/mL; 7 d) monohydrate maintains the viability, proliferation and expression of undifferentiated markers of H9 human embryonic stem cells for up to 7 days without medium change, and reduces apoptotic cell death of newly seeded dissociated cells and preformed cell clusters within 3 days without medium change^[5].
Doxycycline (1 μg/mL; 30-72 d) monohydrate supports long-term subculture of H9, HSF6 human embryonic stem cells as well as Retro-1, Lenti-1, Pro-1 human induced pluripotent stem cells. The culture medium is replaced every 3 days, and the growth rate remains consistent with that under the standard daily medium change condition during passages 5 to 12^[5].
Doxycycline (1 μg/mL; 72 d) monohydrate maintains normal karyotype, expression of undifferentiated markers and pluripotency (the ability to differentiate into all cells of the three germ layers in vitro) of H9 human embryonic stem cells that are subcultured 12 times with medium replacement every 3 days^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:	LNT-229, G55 and U343
Concentration:	1-10 µg/mL
Incubation Time:	96 h
Result:	Reduced the cell density at a dose of 10 µg/mL.

In Vivo

Doxycycline (25-50 mg/kg; p.o.; twice daily; 10 days) monohydrate exerts dose-dependent toxic effects on male Wistar rats: a dosage of 50 mg/kg twice daily for 10 consecutive days causes 30% mortality, cardiomyopathy, and significant elevation of biomarkers for muscle and cardiac injury; whereas a dosage of 25 mg/kg twice daily for 10 consecutive days only induces mild skeletal muscle injury without cardiac toxicity^[1].
Doxycycline (60 mg/kg; intraperitoneal injection; once daily for 15 consecutive days) monohydrate significantly inhibits the growth of CD44v9-expressing prostate cancer xenografts by reducing the proliferation of CD44v9-positive cells^[4].
Supplementary culture of H9 human embryonic stem cells (H9 hESCs) with Doxycycline (1 μg/mL; medium changed every 3 days; up to passage 12) monohydrate maintains their pluripotency and enables in vivo teratoma formation, which contains all three embryonic germ layers^[5].

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Doxycycline (oral gavage; 200 or 800 mg/kg; once daily; 3 months) reduces MMP-9 activity in untreated HT mice in a dose-dependent manner^[3].
Doxycycline and Tetracycline (HY-A0107), act systemically after absorption from the upper gastrointestinal tract. The main advantage of Doxycycline over Tetracycline is its longer activity, and it can be taken twice or once a day. The peak concentration of both agents is similar, but in the case of Doxycycline the time to peak concentration is shorter, and half life is significantly longer^[6].

Doxycycline (Dox) is often used as an inducer in molecular biology studies to induce gene expression. In cells or model animals that have constructed tetracycline induced expression systems (Tet-On/Tet-Off systems), the expression of target genes can be precisely controlled by adding or removing Dox^[7]^[8].
Dose reference for Dox induction^[7]^[8]:
(1) Model animal: male Sprague-Dawley rats
Tet regulatory system: 20-3000 ppm of Dox is supplied in diet.
(2) Model animal: Cags mice
Tet regulatory system: 625 ppm of Dox is supplied in diet.

Induction of Modeling ON-OFF System (Gene expression regulation)^[6]^[7]^[8]

Background

Doxycycline is often used as an inducer in molecular biology research to induce gene expression. In cells or model animals that have constructed a Tetracycline (Tet; HY-A0107) inducible expression (Tet-ON/Tet-OFF) system, the expression of the target gene can be precisely controlled by adding or removing Doxycycline. Doxycycline can act as an inhibitor of transcriptional activation in the Tetracycline (Tc)-controlled transactivation (tTA) system, and as an inducer of transcriptional activation in the "reverse tTA' system. Doxycycline and Tetracycline both act systemically after being absorbed by the upper gastrointestinal tract. In comparison, the main advantage of Doxycycline is that it has a longer activity and can be taken twice or once a day. Although the peak concentrations of the two are similar, Doxycycline takes a shorter time to reach peak concentration and has a significantly longer half-life.

Specific Modeling Methods

Rat^[8]: Sprague-Dawley rats • male • adult middle-aged (12-month-old)
Administration: (for GDNF as targeted gene) 3g/kg (dietary with regular food) • po • once daily for 6 days

Note

(1) Recommend use the recombinant adeno-associated virus (rAAV)-based bicistronic tetracycline (tet)-OFF construct was used for dynamic control of GDNF (target gene) expression during long-term expression^[7].
(2) 3 g/kg dietary DOX produced DOX serum levels equivalent to 1mg/ml DOX in drinking water.

Modeling Indicators

Molecular changes: The expression level of the target gene decreases.

Phenotype changes: The positively correlated phenotype corresponding to the target gene is alleviated.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Heterozygous (HT) Col3a1 knockout mouse model^[3]
Dosage:	25-100 mg/kg/day
Administration:	po, added to feed for 3 months
Result:	Restored collagen content to levels comparable to those in wildtype mice. Prevented the vascular lesion.

Molecular Weight

462.45

Formula

C₂₂H₂₆N₂O₉

CAS No.

17086-28-1

Appearance

Solid

Color

Light yellow to yellow

SMILES

C[C@@]([C@]([C@]1([H])O)([H])C2=C(O)[C@@]3(O)[C@]1([H])[C@@](N(C)C)([H])C(O)=C(C(O)=N)C3=O)([H])C4=C(C2=O)C(O)=CC=C4.O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 200 mg/mL (432.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1624 mL	10.8120 mL	21.6240 mL
5 mM	0.4325 mL	2.1624 mL	4.3248 mL
10 mM	0.2162 mL	1.0812 mL	2.1624 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (10.81 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (10.81 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.95%

Select Batch:

Data Sheet (293 KB) SDS (392 KB)

COA (257 KB) HNMR (317 KB) RP-HPLC (246 KB) MS (71 KB)

Handling Instructions (2659 KB)

References

[1]. El-Neweshy MS, et al. Experimental doxycycline overdose in rats causes cardiomyopathy. Int J Exp Pathol. 2013;94(2):109-114. [Content Brief]

[2]. Zhang L, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017;16(8):737-745. [Content Brief]

[3]. Chang M Y, Rhee Y H, Yi S H, et al. Doxycycline enhances survival and self-renewal of human pluripotent stem cells[J]. Stem cell reports, 2014, 3(2): 353-364.

[4]. Matsumoto T, et al. Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity[J]. Oncogenesis, 2017, 6(11): 397.

[5]. Chang MY, et al. Doxycycline supplementation allows for the culture of human ESCs/iPSCs with media changes at 3-day intervals. Stem Cell Res. 2015;15(3):608-613. [Content Brief]

[6]. Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17(11):1857-67. [Content Brief] [Content Brief]

[7]. Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8. [Content Brief]

[8]. Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93(2):167-73. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1624 mL	10.8120 mL	21.6240 mL	54.0599 mL
	5 mM	0.4325 mL	2.1624 mL	4.3248 mL	10.8120 mL
	10 mM	0.2162 mL	1.0812 mL	2.1624 mL	5.4060 mL
	15 mM	0.1442 mL	0.7208 mL	1.4416 mL	3.6040 mL
	20 mM	0.1081 mL	0.5406 mL	1.0812 mL	2.7030 mL
	25 mM	0.0865 mL	0.4325 mL	0.8650 mL	2.1624 mL
	30 mM	0.0721 mL	0.3604 mL	0.7208 mL	1.8020 mL
	40 mM	0.0541 mL	0.2703 mL	0.5406 mL	1.3515 mL
	50 mM	0.0432 mL	0.2162 mL	0.4325 mL	1.0812 mL
	60 mM	0.0360 mL	0.1802 mL	0.3604 mL	0.9010 mL
	80 mM	0.0270 mL	0.1351 mL	0.2703 mL	0.6757 mL
	100 mM	0.0216 mL	0.1081 mL	0.2162 mL	0.5406 mL